MCM2 was considered as a potential therapeutic target for cancer treatment, and the level of MCM2 could predict poor prognosis for osteosarcoma [21], gastric cancer [22], lung adenocarcinoma [23], diffuse large B cell lymphoma [24], and esophageal cancer [25]. This evidence concerns the gene MCM2 and osteosarcoma.